ArticleDoklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections2026
Plasma Extracellular Vesicles from Glioblastoma Patients Affect Phenotype and Activate Receptor Tyrosine Kinases in Glioblastoma Cells.
Article in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles are important transmitters of oncogenic signals between cancer cells. Despite numerous studies of vesicles from model glioblastoma (GBM) cells, information on the effects of vesicles from GBM patients on the development of model GB cells is lacking. In this study, plasma vesicles from healthy donors (HVs) and GBM patients (GVs) were studied to affect expression of differentiation (GFAP and GLT-1) and stemness (CD9 and CD133) markers and expression and activation of the oncogenic receptor tyrosine kinases EGFR and PDGFRβ in GBM cells (primary GBM011 and model U251 MG cell lines) and rat and human normal astrocytes. GVs reduced GFAP expression in GBM011 cells and stimulated GFAP and CD9 expression in U251 MG cells. GVs increased EGFR and PDGFRβ expression in both GBM cell lines and enhanced EGFR (Y1086) and PDGFRβ (Y751) phosphorylation in U251 MG cells. HVs stimulated CD9 expression in U251 MG cells and PDGFRβ expression in GBM011 cells, but decreased EGFR and PDGFRβ expression in U251 MG cells. Thus, both GVs and HVs influence the GBM phenotype and receptor tyrosine kinase activation.
Indexed as
Identifiers
42550422What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.